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Toshiro Niki,3,4 Mitsuomi Hirashima,3,4 Ben Joosten,5 Koen van den Dries,5 Alessandra Cambi,5 Carl G. Figdor,1,7
and Annemiek B. van Spriel1,7,8,*
SUMMARY
Endogenous extracellular Galectins constitute a novel mechanism of membrane protein organization
at the cell surface. Although Galectins are also highly expressed intracellularly, their cytosolic func-
tions are poorly understood. Here, we investigated the role of Galectin-9 in dendritic cell (DC) surface
organization and function. By combining functional, super-resolution and atomic force microscopy
experiments to analyze membrane stiffness, we identified intracellular Galectin-9 to be indispensable
for plasma membrane integrity and structure in DCs. Galectin-9 knockdown studies revealed intracel-
lular Galectin-9 to directly control cortical membrane structure bymodulating Rac1 activity, providing
the underlying mechanism of Galectin-9-dependent actin cytoskeleton organization. Consequent to
its role in maintaining plasma membrane structure, phagocytosis studies revealed that Galectin-9
was essential for C-type-lectin receptor-mediated pathogen uptake by DCs. This was confirmed by
the impaired phagocytic capacity of Galectin-9-null murine DCs. Together, this study demonstrates
a novel role for intracellular Galectin-9 in modulating DC function, which may be evolutionarily
conserved.
INTRODUCTION
Dendritic cells (DCs) constitute the major group of antigen-presenting cells that constantly patrol the body
for microbes and are essential for linking innate and adaptive immune responses (Banchereau and Stein-
man, 1998). DCs are equipped with a diverse membrane receptor repertoire to take up pathogens
including Toll-like receptors, scavenger receptors, and C-type lectins, such as the mannose receptor
and the dendritic cell-specific intercellular adhesion molecule grabbing non-integrin receptor (DC-
SIGN) (Banchereau et al., 2000; Savina and Amigorena, 2007; Buschow et al., 2012; Heinsbroek et al.,
2008; Geijtenbeek et al., 2000). Engagement of these receptors with their ligand is accompanied by cyto-
skeletal changes, which allow for the capture and engulfment of phagocytic targets (Sano et al., 2003;
Baranov et al., 2016). Actin polymerization is instrumental in forming a nascent phagosome for pathogen
engulfment, and actin-driven mechanical forces enable pathogen internalization (May et al., 2000). In addi-
tion, phagocytosis is dependent on plasmamembrane organization and loss of membrane structure results
in impaired pathogen recognition, defective migration, and compromised immunological synapse forma-
tion (Alvarez et al., 2008; Heuze et al., 2013; Buschow et al., 2012). Galectins, a family of ß-galactoside-bind-
ing proteins, have been recently identified as a novel mechanism of membrane organization (Lajoie et al.,
2009; Elola et al., 2015; Nabi et al., 2015) due to their ability to interact with and cross-link specific carbo-
hydrate structures. As such, Galectins can simultaneously interact with multiple glycoconjugates, thereby
regulating the dynamics of glycosylated-binding partners, limiting receptor internalization, and establish-
ing membrane microdomains (Elola et al., 2015). Notably, Galectins are also abundantly expressed intra-
cellularly, although their cytosolic functions are not well characterized (Hsu et al., 2015a; Johannes et al.,
2018; Liu et al., 2002; Liu and Rabinovich, 2005). Recently, Galectins have been discovered as novel regu-
lators of several immune processes, such as T cell homeostasis, inflammation, and immune disorders
(Sundblad et al., 2017; Thiemann and Baum, 2016; de Oliveira et al., 2015; Rabinovich and Toscano, 2009).
Galectin-9 was first discovered as an eosinophil chemoattractant, and to date, most studies have focused
on studying Galectin-9 in inflammation or infection processes (Jost et al., 2013; Curciarello et al., 2014; Hsu
et al., 2015b). Extracellular Galectin-9 has been implicated in inhibiting T cell immunity by promoting T cell
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Figure 1. Galectin-9 Is Required for Dendritic Cell Function
(A and B) moDCs were transfected with gal9 siRNA and/or gal3 siRNA or a non-targeting siRNA (NT). Surface only (A) and
total (B) Galectin-9 and Galectin-3 knockdown were confirmed by flow cytometry 48 h after transfection. Red population,
NT siRNA; blue population, gal9 and gal3 siRNAs transfectedmoDCs; black population, isotype control. Numbers in inset
indicate geometrical mean fluorescence intensity.
(C) NT, gal9, and/or gal3 siRNA-transfected cells were challenged with zymosan for 60 min, after which cells were fixed,
stained, and the phagocytic index calculated. Graphs show representative results for one donor. Each dot represents
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apoptosis and differentiation into regulatory T cells (Anderson et al., 2007; Bi et al., 2008; Zhu et al., 2005).
Furthermore, extracellular Galectin-9 acts as a suppressor of B cell signaling by binding to the B cell recep-
tor (Cao et al., 2018; Giovannone et al., 2018). Although these studies indicate that Galectin-9 plays an
inhibitory role on lymphocytes, its function in myeloid cells remains poorly understood. Moreover,
Galectin-9 is also highly expressed intracellularly, and although implicated in protein-protein interactions
and mRNA splicing (Liu et al., 2002; Sundblad et al., 2017; Heusschen et al., 2013), the function of cytosolic
Galectin-9 in the immune system continues to be ill defined.
Here, we demonstrate that intracellular Galectin-9 is essential for sustaining cortical actin cytoskeleton
rigidity and phagocytosis in DCs. Our work indicates a novel evolutionary conserved mechanism by which
intracellular Galectins stabilize plasma membrane structure by actin cytoskeleton reorganization.
RESULTS
Galectins Are Essential in Governing Human Dendritic Cell Function
The role of Galectins in the initiation of the immune response is poorly understood, and although Galectin-
3 has been implicated in macrophage-mediated uptake in mice (Sano et al., 2003), few studies have been
performed to elucidate Galectin function in DCs (de Kivit et al., 2017; Leskela et al., 2015; Hsu et al., 2015b;
Dai et al., 2005). To address this question, we generated DCs lacking Galectin-3 and/or Galectin-9 by elec-
troporating human monocyte-derived dendritic cells (moDCs) with either a specific galectin small inter-
fering RNA (siRNA) (gal3 and/or gal9) or a non-targeting (NT) siRNA control before challenge them with
fluorescein isothiocyanate (FITC)-labeled zymosan particles, a fungal cell wall extract (de la Rosa et al.,
2005). Subsequent immunolabeling without permeabilization using an antibody directed against FITC al-
lowed for selective labeling of membrane-bound particles. Galectin-9 and Galectin-3 protein knockdowns
were confirmed by flow cytometry showing that both proteins were depleted to a similar extent (70%, Fig-
ures 1A and 1B). The efficiency of Galectin knockdown was comparable between cells transfected with a
single siRNA or with dual siRNA, andGalectin-9 knockdown (Gal-9 KD) did not affect Galectin-3 expression,
or vice versa (Figure S1). Depletion of Galectin-9 impaired particle uptake to a greater extent when
compared with that observed upon Galectin-3 knockdown (Figures 1C, 1D, and 1E). Moreover, there
was no additive effect of knocking down both Galectin-9 and Galectin-3 (Figure 1E). Taken together, these
data demonstrate that Galectins are required for phagocytosis by DCs, and indicates that Galectin-9 is a
major player in this process.
Galectin-9 Is Essential for Phagocytosis by Dendritic Cells
We previously identified Galectin-9 as part of the DC-SIGN-mediated, a phagocytic receptor present in
immature DCs, phagosomes, although no functional studies were performed to assess the role of Galec-
tin-9 in DC function (Buschow et al., 2012; Manzo et al., 2012; Liu et al., 2017; Cambi et al., 2003; Geijtenbeek
et al., 2000). Co-immunoprecipitation experiments revealed DC-SIGN association with Galectin-9 in DCs,
demonstrating their molecular interaction (Figure 2A). To examine whether this interaction occurs in the
cytosolic compartment and/or at the extracellular matrix, co-immunoprecipitations were performed on
lactose-treated moDCs and in the presence of lactose to prevent unspecific binding of Galectin-9 to
DC-SIGN during cell lysis. Lactose impairs cell surface glycan-based interactions mediated by Galectins
by competing for their major ligands, which dissociates Galectins from the cell surface (Lajoie et al.,
2007; Cambi et al., 2009). As shown, addition of lactose successfully removed Galectin-9 from the surface
of moDCs (Figure S2A). Nonetheless, Galectin-9 was found to still bind DC-SIGN, albeit to a lesser extent
than in the untreated control (Figure 2B). These data indicate that Galectin-9 binds to DC-SIGN both extra-
and intracellularly. To investigate the role of Galectin-9 in DC-SIGN-mediated phagocytosis, Gal-9 KD and
NT control (referred to as wild-type [WT]) DCs were challenged with zymosan particles. Galectin-9 protein
knockdown (90%) was confirmed by flow cytometry (Figure S2B) and western blotting (Figure S2C). No
Figure 1. Continued
phagocytic index obtained for one image field; 20–30 image fields were analyzed per condition, and each image field
contained 10–20 cells.
(D) Representative images from results shown in (C).
(E) Quantification and statistical analysis of experiments depicted in (D). Results show the mean G SEM for four
independent donors. Unpaired Student’s t test was conducted between NT and gal9 siRNA- and between NT and gal3
siRNA-transfected cells.
*p < 0.05, **p < 0.005, ***p < 0.0001. See also Figure S1.
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Figure 2. Galectin-9 Is Required for Optimal Phagocytic Capacity in DCs
(A) moDCs were lysed and whole-cell extract prepared for incubation with anti-DC-SIGN antibody (H200) or isotype
control (total rabbit IgG). Immunoprecipitated (IP) complexes were resolved and probed with DC-SIGN- and Galectin-9-
specific antibodies. Graph shows quantification of Galectin-9 content of each sample using ImageJ.
(B) moDCs were treated with 35mM lactose for 48 h before being lysed as per (A). IP complexes were resolved and probed
with DC-SIGN- and Galectin-9 specific antibodies. Graph shows quantification of Galectin-9 content of each sample using
ImageJ.
(C) NT or gal9 siRNA-transfected cells were challenged with zymosan for the indicated time points. After this time, cells
were fixed, stained, and phagocytic indexes calculated for each time point. Graphs show representative results for one
donor. Each dot represents phagocytic index obtained for each microscopic field, each of which contained 10–20 cells.
(D) Quantification and statistical analysis of experiments shown in (C). Twenty frames were analyzed for each donor and
transfection. Results show the mean value G SEM for four independent donors. Unpaired Student’s t test was
conducted between NT and gal9 siRNA-transfected cells for all time points.
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significant differences in zymosan binding were observed between NT and gal9 siRNA-transfected DCs
(Figure S2D), implying that Galectin-9 is not required for particle binding. To study the involvement of
Galectin-9 in particle uptake, the phagocytic index was calculated for each of the conditions and specified
time points (Figures 2C, 2D, and S2E). Gal-9 KD resulted in impaired zymosan internalization 60 min after
challengingmoDCs (Figure 2D). Quantification of the number of particles internalized per cell revealed that
the impaired uptake upon Gal-9 KD is likely due to a decrease in the number of zymosan particles internal-
ized per cell rather than a decrease in the total amount of cells able to uptake particles (Figure 2E). Gal-9 KD
did not alter DC-SIGN membrane expression or receptor internalization excluding that the uptake defect
was due to deficient receptor surface levels (Figure S3). Next, WT and Gal-9 KD moDCs were incubated
with a DC-SIGN-blocking antibody (clone AZN-D1) or isotype control before challenging them with
zymosan particles. AZN-D1 does not induce DC-SIGN signaling and has a modified Fc region that cannot
be recognized by the Fc receptors expressed on DCs (Geijtenbeek et al., 2000; Tacken et al., 2005). As ex-
pected, blocking DC-SIGN resulted in defective zymosan uptake by NT-transfected moDCs, although
zymosan uptake was unaffected by the addition of isotype controls (Figures S4A and S4B). Analysis per-
formed on multiple donors confirmed our observations, and zymosan uptake was significantly impaired
upon DC-SIGN blocking, indicating that DC-SIGN is the major receptor for zymosan in DCs (Figure S4C).
These results demonstrate that Galectin-9 is an essential component in DC-SIGN receptor-mediated
uptake by DCs.
Zymosan uptake experiments were also performed with murine bone marrow-derived dendritic cells
(BMDCs) from WT and galectin-9-deficient (galectin9 /) mice. In line with human DCs, lack of Galectin-
9 in murine DCs resulted in defective phagocytic capacity, suggesting an evolutionarily conserved role
for Galectin-9 in phagocytosis (Figures 3A and 3B). To investigate the effect of Galectin-9 in DC-mediated
immunity against fungal pathogens, galectin-9-null mice were immunized with heat-inactivated Candida
albicans and DC function analyzed (Figure 3C). Although we were not able to quantify phagocytosis in vivo,
murine DCs lacking Galectin-9 displayed a significant decrease in cytokine secretion upon infection,
indicating poor initiation of a proper immune response (Figures 3D–3G).
Intracellular Galectin-9 Controls Plasma Membrane Structure in Dendritic Cells
To examine whether the extra- or the intracellular pool of Galectin-9 was responsible for the defect in
phagocytosis, moDCs were treated with lactose to remove extracellular galectins from the cell surface
before being challenged with zymosan particles. Although lactose treatment effectively reduced the sur-
face levels of Galectin-9 and Galectin-3 (Figures 4A and 4B), no effects on zymosan uptake were observed
compared with untreated cells (Figure 4C). Lactose was also added during zymosan incubation, and no dif-
ferences in the phagocytic index of moDCs treated with lactose were observed, regardless of whether
lactose was present during zymosan incubation (Figure S5). This indicates that the intracellular pool of
Galectin-9 is responsible for particle uptake by moDCs and that particle binding and internalization are
independent of Galectin-9-mediated interactions at the cell surface. These findings led us to hypothesize
that Galectin-9 may interact with specific cytoskeleton components, which could alter the stability and/or
the formation of phagosomes. To address this, Gal-9 KD andWT DCs were analyzed for their uptake ability
upon treatment with cytochalasin D (cytD), which blocks actin polymerization by its binding to actin fila-
ments. Addition of cytD resulted in a significant decrease of particle uptake in WT cells in contrast to
Gal-9 KD moDCs that were not affected by cytD after challenging cells for 60 min (Figure 5A). Earlier
time points were also analyzed, but DCs were still unable to take up any particles due to the inhibition
of the actin cytoskeleton polymerization (Figures S6A and S6B). We excluded that this was due to a differ-
ence in particle binding betweenWT and Gal-9 KD cells (L. Querol Cano, unpublished data) or cell viability,
which was not affected upon treatment with cytD (Figure S6C). Similar results were obtained when DCs
were treated with increasing concentrations of cytD, confirming gal9 siRNA-transfected cells to be less sen-
sitive to actin disruption than their WT counterparts (Figure S6D). To corroborate an impairment in the actin
cytoskeleton upon Galectin-9 depletion, levels of F-actin were measured in WT and Gal-9 KD cells moDCs.
A decrease of approximately 20% in the total levels of F-actin was seen in moDCs depleted for Galectin-9,
confirming a specific effect for this lectin in the actin cytoskeleton arrangement (Figures 5B and 5C).
Figure 2. Continued
(E) NT or gal9 siRNA-transfected cells were challenged as per (C) and the number of internalized zymosan particles quantified for each frame. Ten to twenty
frames were analyzed for each condition. Data represent mean percentage of DCs that had internalized the specified number of particles of one
representative donor out of three independent experiments. For statistical analysis two-way ANOVA followed by a Bonferroni post hoc test was applied.
n.s.: p > 0.05; *p < 0.05, **p < 0.005. See also Figures S2–S4.
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Figure 3. Galectin-9 Function in DC Is Conserved between Mouse and Human and Alters Dendritic Cell-Mediated
Immune Responses In Vivo
(A) Bone marrow-derived dendritic cells (BMDCs) obtained from either wild-type (control) or galectin-9-null
(galectin-9 /) mice were seeded on coverslips, challenged with zymosan for 60 min, and the phagocytic index
calculated. Results show the mean phagocytic index valueG SEM for three independent mice. Unpaired Student’s t test
was conducted between wild-type and galectin-9 / mice. *p < 0.05.
(B) Representative images from results shown in (A). Scale bar, 10 mm.
(C–G) (C) Scheme depicting work protocol to assess anti-fungal immunity in galectin-9-null animals. Four wild-type (WT) and
galectin-9 / mice were injected with heat-inactivated Candida albicans. Three hours after injection, lymph nodes and spleen
were removed, single-cell suspensions made, and cells seeded onto 96-well plates. Spleen cell suspensions were re-stimulated
iScience 22, 240–255, December 20, 2019 245
Experiments performed with galectin-9 / murine BMDCs confirmed this defect in cellular actin content
(Figures 5D and 5E). Furthermore, confocal imaging showed that the percentage of F-actin-positive phag-
osomes was reduced upon Gal-9 KD in moDCs challenged with zymosan particles by approximately 40%
(Figures 5F and 5G) in line with our previous observation (Figure 5B). These data suggest that depletion of
Galectin-9 leads to reduced actin filament formation both under basal conditions and around phago-
somes. To further verify Galectin-9 involvement in directly controlling the actin cytoskeleton, super-resolu-
tion laser scanning microscopy was performed on ventral plasma membrane sheets of moDCs. These
studies demonstrated that Galectin-9 closely associates with the cortical actin cytoskeleton under basal
conditions (Figure 6).
To unravel the mechanism underlying Galectin-9 function in plasma membrane integrity and structure, we
exploited atomic force microscopy (AFM) to analyze the cellular stiffness of moDCs transfected with
either NT or gal9 siRNA. Nanomechanical probing of the cells was achieved by obtaining a series of
force-distance curves on selected points of the cell surface. A sharp non-functionalized cantilever with
a radius of approximately 35 nm was brought into contact with a flat area of a single DC attached to a
glass coverslip applying a mechanical force (Figure 7A). The use of a combined bright-field AFM setup
allowed for accurately positioning the cantilever over specific areas of interest on the cell surface (Fig-
ure 7B). Analysis of the approach force-distance curves obtained for each point of interest allowed calcu-
lation of the cytoskeletal stiffness using the linearized Sneddon equation (Figure 7C). For this purpose,
minimum and maximum fit boundaries (shown in blue) were defined respectively as 10% and 70% of
the maximum force after baseline correction (Figure 7C). The portion of the curves that was used for
fitting with the linearized model is shown in purple, and the separation distance that corresponds to
this fit region is in the range of 200–600 nm (Figure 7C). Given that the thickness of the lipid bilayer is
approximately 4 nm (Yokokawa et al., 2008), it is plausible to presume that the underlying cytoskeletal
structures such as cortical actin and peripheral cytoplasm were also probed in our experiments. The
mechanical characterization performed on DCs shows that moDCs lacking Galectin-9 have a decreased
cytoskeletal rigidity compared with their WT counterparts (Figure 7D), in line with the defect in their cyto-
skeleton previously observed.
As it is well known that actin polymerization is mediated by small GTPases of the Rho family including Rac1
(Caron and Hall, 1998; May et al., 2000; Swanson, 2008; Norman et al., 1996), we investigated the effect of
Galectin-9 depletion on Rac1 activation by specifically measuring its GTP-bound fraction using a G-LISA
colorimetric assay. Incubation of control moDCs with zymosan particles resulted in a fast induction of
Rac1-GTP activity already after 5-min stimulation (Figures 8A and 8B), which was sustained in time (Figures
8A and 8C). Depletion of Galectin-9 abrogated Rac1 induction, and no increase in its GTP-bound form
could be observed upon zymosan stimulation in moDCs transfected with gal9 siRNA at any of the time
points analyzed (Figures 8A–8C). The recruitment of total Rac1 to nascent phagocytic cups was also
impaired upon Gal-9 KD (Figures 8D–8F), suggesting that Galectin-9 promotes both Rac1 recruitment
and activity on phagosomes.
Taken together, intracellular Galectin-9 controls plasma membrane structure via modulating Rac1 activity
and actin polymerization, which underlies Galectin-9 requirement for phagocytosis in DCs.
DISCUSSION
Galectins have gained increasing interest for their role as extracellular organizers of plasma membrane
components via glycan-mediated interactions. Nonetheless, their mechanism of action remains poorly
understood, and in particular, their intracellular functions are ill-defined (Buschow et al., 2012). Here,
we identified a previously unrecognized function for intracellular Galectin-9 in actin cytoskeleton reorga-
nization and report a novel, functional interaction between Galectin-9 and the C-type lectin receptor
DC-SIGN at the cytosol of DCs. Several members of the Galectin family are expressed in the cytosol,
and some, such as Galectin-1 or Galectin-3 are predominantly intracellular proteins (Liu et al., 2002;
Figure 3. Continued
with C. albicans, and 24 h after seeding cytokine secretion was measured in supernatants by ELISA. Tumor necrosis
factor (TNF)-a production in spleen (D) or lymph node (E) samples. Interleukin (IL)-12 production in spleen (F) or lymph
node (G) samples. Graph shows the mean value G SEM for four animals. Unpaired Student’s t test was conducted
between WT and Gal9 KO cells. *p < 0.05.
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Wilson et al., 1989; Clerch et al., 1988; Hubert et al., 1995). Very little is known regarding the localization
and function of cytoplasmic Galectin-9, although it has been implicated in protein folding and signal
transduction (John and Mishra, 2016; Vasta et al., 2012). Our study now demonstrates that the large
intracellular pool of Galectin-9 is responsible for the phagocytic capacity in DCs by modulating plasma
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Figure 4. Intracellular Galectin-9 Is Responsible for Modulating Dendritic Cell Function
(A and B) moDCs were treated with 35 mM lactose for 48 h, and removal of extracellular (A) but not intracellular (B)
Galectin-9 and Galectin-3 expression was confirmed by flow cytometry. Red population, untreated cells; blue population,
lactose-treated cells; black population, isotype control. Numbers in inset indicate gMFI. Panels depict representative
results for one donor, and graphs show the mean phagocytic index G SEM for three independent donors. Unpaired
Student’s t test was conducted between untreated control and lactose-treated cells.
(C) Control or lactose-treated cells were challenged with zymosan for 60 min. Cells were then fixed, stained, and the
phagocytic index calculated. Graphs show the meanG SEM for three independent donors. Unpaired Student’s t test was
conducted between untreated control and lactose-treated cells. n.s.: p > 0.05, *p < 0.05. See also Figure S5.
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Figure 5. Galectin-9 Modulates Cellular Actin Cytoskeleton
(A) NT or gal9 siRNA-transfected moDCs were pretreated with 1.25 mg/mL cytochalasin D (cytD) for 10 min before being
challenged with zymosan for 60 min. Cells were then fixed, stained, and the phagocytic index calculated. Twenty frames
were analyzed for each condition and donor. Data represent mean average phagocytic index G SEM for one
representative donor out of three independent experiments. Unpaired Student’s t test was conducted between NT and
gal9 siRNA-transfected cells.
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membrane structure, revealing a novel function for Galectins in cytoskeleton remodeling. This was
observed in both human and murine cells, which indicates Galectin-9 as an evolutionarily conserved lectin
required for maintaining the cortical cytoskeleton structure and function in DCs. Our data support a
model in which Galectin-9 is essential for DC-SIGN-mediated phagocytosis, by (1) maintaining plasma
membrane and cortical actin stiffness and (2) controlling receptor function (Figure 9). We identified
that the underlying mechanism involves Galectin-9-dependent activation and recruitment of Rac1-GTP
upon particle incubation, which triggers actin polymerization and the subsequent formation of phago-
cytic cups.
In line with this, our AFM studies demonstrate that Galectin-9-depleted cells have a less rigid plasma
membrane and cortical cytoskeleton, rendering them unable to adequately modify their structure upon
Actin Galectin-9 Merged
Figure 6. Galectin-9 Closely Associates with the Actin Cytoskeleton
Ventral plasma membrane sheets from day 5 moDCs were stained for actin and Galectin-9 and imaged with super-
resolution microscopy. A representative plasma membrane sheet out of four independent experiments is shown. Gamma
correction (0.2) was applied to enhance the contrast of the actin image. Lower images: magnification of the area indicated
in the upper images. Scale bar, 10 mm. Arrows indicate sites of Galectin-9 and actin colocalization.
Figure 5. Continued
(B) Actin levels were analyzed by flow cytometry in NT and gal9 siRNA-transfected moDCs. Results are expressed as
percent gMFI of gal9 siRNA-transfected cells relative to their NT control. Data represent mean average % gMFI for three
independent experiments G SEM. One-way t test was conducted.
(C) Representative histogram for actin expression after Galectin-9 knockdown. Gray area, NT siRNA-transfected moDCs;
red area, gal9 siRNA-transfected moDCs; black dotted line, isotype control. Numbers in inset indicate gMFI.
(D) Actin levels of BMDC obtained from wild-type (control) or galectin-9 /mice were analyzed by flow cytometry. Data
represent mean average gMFI for three independent mice G SEM.
(E) Representative histogram for actin expression. Gray line, control BMDCs; red line, galectin-9 / BMDCs. Numbers in
inset indicate gMFI.
(F) Representative confocal images of F-actin rings in moDCs transfected as in (A) and challenged with zymosan particles
for 15 min.
(G) Quantification of the percentage of F-actin-positive phagosomes of experiments shown in (F).
Data represent mean average G SEM. n.s.: p > 0.05, *p < 0.05, **p < 0.005, ***p < 0.001. See also Figure S6.
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Figure 7. Galectin-9 Alters Cytoskeletal Membrane Rigidity
(A) Schematic AFM single-cell elasticity measurement setup showing an overview of the AFM cantilever in contact with the
DC and the cantilever movement used to measure the change in cantilever deflection.
(B) Optical image of gal9 siRNA-transfected moDCs obtained during the mechanical probing of the cell. White dot shows
the position of the tip, and the red cross depicts the region of interest at the membrane that was indented with the
cantilever.
(C) Representative force-distance curves obtained on gal9 siRNA-transfected (black) and NT siRNA (red) moDCs and
curve-fitting approach to determine the Young’s modulus of elasticity. Blue lines correspond to upper- and lower-fit
boundaries (70% and 10% of the maximum force, respectively); purple lines show fitted portion of the curves used to
calculate Young’s modulus.
(D) Young’s modulus of elasticity was calculated by fitting the force-distance curves indicated in (C). Data
represent mean average Young’s modulus of elasticity G SEM of three independent donors, and each data point
shows the average value for three different locations for each moDC. Ten to thirty cells were analyzed for each
donor in each independent experiment. Unpaired Student’s t test was conducted between NT and gal9 siRNA-
transfected cells. ***p < 0.001.
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Figure 8. Galectin-9 Promotes Phagosomal Rac1 Activity
(A) NT and gal9 siRNA-transfected moDCs were challenged with zymosan particles for the indicated time points. After
this time, cells were lysed, total protein was quantified, and Rac1-GTP activation was determined. Results are expressed
as fold increase Rac1-GTP levels and relative to the unstimulated corresponding sample. Data represent mean average
Rac1-GTP fold inductionG SEM of three independent donors. Unpaired Student’s t test was conducted between NT and
gal9 siRNA-transfected cells.
(B and C) Each symbol represents one independent donor, and lines connect paired NT and gal9 siRNA-transfected
moDCs after stimulation with zymosan for either 5 min (B) or 30 min (C).
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particle engulfment. Moreover, inhibition of actin polymerization did not affect the phagocytic ability of
Gal-9 KD cells in contrast to WT cells. Although actin executes a pivotal function in phagocytosis, little is
known regarding the mechanisms that govern F-actin recruitment to a nascent phagosome due to the
lack of high-resolution data (Baranov et al., 2016). Our data support a new concept in which intracellular
Galectin-9 is required for actin polymerization, directly controlling plasma membrane rigidity, by
enhancing the activity of the actin-binding protein Rac1. In line with this, Galectin-1 has been recently
shown to re-activate F-actin protein levels (Quinta et al., 2016). Similarly, intracellular Galectin-3 has
been proved to enhance phagocytosis in macrophages by its interaction with F-actin in the phagocytic
cups (Sano et al., 2003; Serizawa et al., 2015). Intracellular ligands have been proposed to bind Galectins
through protein-protein interactions independent of carbohydrate-mediated recognition, although
whether both proteins interact directly or through an intermediary molecule is not known (de Oliveira
et al., 2015; Johannes et al., 2018; Shimura et al., 2004). Whether Galectin-9 function in our study is car-
bohydrate independent remains to be elucidated, but knockdown of Galectin-9 in the presence of other
Galectins was sufficient to induce defects in actin polymerization and cellular rigidity in DCs. DC-SIGN is
known to interact with actin and Lsp-1, an F-actin-interacting protein through its cytoplasmic tail (Smith
et al., 2007), which likely allows for extracellular particle binding, plasma membrane deformation, and
actin polymerization to occur simultaneously. Moreover, DC-SIGN signaling results in enhanced RhoA-
GTPase activity (den Dunnen et al., 2009; Hodges et al., 2007). Our data now support that depletion of
intracellular Galectin-9 is sufficient to disrupt the cytosolic complex of DC-SIGN with actin-binding pro-
teins, ultimately impairing cytoskeleton reorganization and causing a reduction in the cellular phagocytic
capacity. We identified Galectin-9 as an integral component of the actin cytoskeleton as well as of the
intracellular DC-SIGN-associated complex, and it is conceivable that Galectin-9 exerts its effects on
the cytoskeleton remodeling by directly linking F-actin filaments, actin remodeling proteins, and DC-
SIGN in a multi-protein complex (Figure 9). Alternatively, Galectin-9 may connect DC-SIGN with other
plasma membrane receptors known to associate with actin, such as CD44, which has been previously
shown to interact with Galectin-9, as a component of DC-SIGN-directed phagosomes in DCs (Wu
et al., 2014; Buschow et al., 2012).
Aside of its direct effects on DC-SIGN, we expect Galectin-9 depletion to have additional effects on the
function of other lectin receptors involved in phagocytosis (mannose receptor, complement receptor 3,
TLR2) (Sung et al., 1983; Xia et al., 1999). To date, extracellular Galectin-9 has been previously shown to
interact with CD44, glucose transporter-2, immunoglobulin E, and Tim-3, a T cell type 1 membrane protein,
known to be involved in T cell apoptosis and phagocytosis of apoptotic cells (Wu et al., 2014; Zhu et al.,
2005). All these interactions, though, are carbohydrate dependent and mediated via glycan-lectin associ-
ations. To the best of our knowledge, no intracellular binding partners have been previously reported for
Galectin-9.
The intracellular functions of Galectin-9 and particularly its role in phagocytosis have not been previously
addressed, and our work is in line with Galectin-3 and Galectin-1 function in particle uptake, highlighting
the broad importance of intracellular Galectins in enhancing cellular uptake (Farnworth et al., 2008; Sano
et al., 2003; Barrionuevo et al., 2007; Caberoy et al., 2012; Linden et al., 2013; Quattroni et al., 2012). Further-
more, our studies with primary DCs demonstrate that disruption of glycan interactions solely alters particle
uptake but not their binding to the cell membrane, which is in agreement with previous findings (Sano et al.,
2003).
In summary, our work demonstrates a novel role for intracellular Galectin-9 in the regulation of the phago-
cytic activity through reorganization of the actin cytoskeleton that underlies plasma membrane rigidity in
Figure 8. Continued
(D) NT or gal9 siRNA-transfected moDCs were challenged with zymosan_FITC for 5 min before being stained for
F-actin (magenta) and Rac1 (blue) and imaged with super-resolution microscopy. A representative confocal image
out of 9 images is shown. Scale bar, 10 mm. Arrows indicate overlap between Rac1 and F-actin signal on
phagocytic cups.
(E) Magnification of representative phagocytic cups in NT and gal9 siRNA-transfected moDCs treated as in (D).
(F) Number of Rac1- and/or F-actin-positive phagocytic cups found on moDCs treated as in (D). Nine images containing
between 20 and 30 cells were analyzed for each condition. Data represent mean average number of phagocytic cupsG
SEM. Unpaired Student’s t test was conducted between NT and gal9 siRNA-transfected cells.
*p < 0.05; **p < 0.01; n.s p > 0.05.
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DCs. Given the plethora of cellular biological processes Galectin-9 is involved in, this novel intracellular Ga-
lectin-9 mechanism of action contributes to the general understanding of plasma membrane structure and
their implications in cell function.
Limitations of the Study
In this study we identified Galectin-9 as novel regulator of the actin cytoskeleton and plasma membrane
structure in DCs. We have also defined and characterized the interaction and functional relationship be-
tween Galectin-9 and the phagocytic receptor DC-SIGN. Further work could be performed to confirm
that both proteins interact intracellularly. Given the cytosolic localization and function of Galectin-9, a
further in-depth characterization of the role Galectin-9 in governing the intracellular signaling pathway
downstream of DC-SIGN would also be pertinent.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.11.019.
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Figure 9. Model of the Role of Galectin-9 in Membrane Rigidity and Particle Uptake
(A) Intracellular Galectin-9 controls polymerization of cortical actin through interacting with C-type lectin phagocytic
receptors and modulating Rac1 activity, which is essential for plasma membrane integrity and successful target uptake.
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Supplemental figure legends 
Figure S1. gal9 and gal3 siRNA do not cause non-specific effects, Related to Figure 1. A and B 
moDCs were transfected with gal9 siRNA and/or gal3 siRNA or a non-targeting siRNA (NT). Total (A) 
or surface bound (B) Galectin-9 and Galectin-3 knockdown were confirmed by flow cytometry 48 h after 
transfection. NT siRNA (grey area), gal9 siRNA or gal3 siRNA transfected moDCs (red area), gal9 and 
gal3 siRNA transfected moDCs (blue area). Black dotted line represents isotype control. Numbers in 
inset indicate geometrical Mean fluorescence intensity (gMFI). C. moDCs were transfected as above 
and surface levels of Galectin-9 and Galectin-3 assessed by flow cytometry. Grey area represent levels 
of Galectin-9 and Galectin-3 in NT siRNA transfected cells and black dotted line=isotype control. 
Numbers in inset indicate gMFI. In left panel: orange area shows levels of Galectin-9 in gal3 siRNA 
transfected cells. Red area depicts Galectin-3 levels in gal9 siRNA transfected cells. In right panel: 
organge area represents Galectin-3 levels in gal9 siRNA transfected cells and red area shows Galectin-
9 levels in gal3 siRNA transfected cells.  
  
Figure S2. Galectin-9 is depleted in dendritic cells upon gal9 siRNA transfection and lactose 
treatment, Related to Figure 2. A moDCs were treated with 35 mM lactose for 48 h and removal of 
extracellular Galectin-9 expression was confirmed by flow cytometry. Black population = untreated cells; 
purple population = lactose treated cells; black dotted line population = isotype control. Numbers in inset 
indicate gMFI. Panels depicts representative results for one donor. B. moDCs were transfected with 
gal9 siRNA or a NT siRNA. Galectin-9 knockdown was confirmed by flow cytometry 48 hours after 
transfection. NT (grey area) or gal9 siRNA-transfected moDCs (red area). Black dotted line represents 
isotype control values. Numbers in inset indicate gMFI. C. Total lysates from NT and gal9 siRNA 
transfected cells were subjected to Western Blot and Galectin-9 expression was analysed. Tubulin was 
used as loading control. Band intensities were quantified using ImageJ and normalised for tubulin. D. 
NT or gal9 siRNA-transfected cells were challenged with zymosan for 60 min. After this time, cells were 
fixed, stained and binding index calculated for each frame analysed. Data represents mean average 
binding index ± SEM of three independent donors. Twenty frames were analysed for each donor and 
transfection. E. Representative images from NT or gal9 siRNA-transfected moDCs 60 min after being 
challenged with zymosan. Scale bar: 25 μm. 
  
Figure S3. Galectin-9 knockdown does not affect cell surface or intracellular DC-SIGN levels, 
Related to Figure 2. moDCs were transfected with either NT or gal9 siRNA and the cell surface levels 
of Galectin-9 and DC-SIGN analysed 24 h (A and B), 48 (C and D) and 72 h (E and F) after transfection 
by flow cytometry. G and H. Intracellular levels of Galectin-9 (G) and DC-SIGN (H) were analysed 48 h 
after transfection with either NT or gal9 siRNA by flow cytometry. Each symbol represents one 
independent donor and lines connect paired NT and gal9 siRNA-transfected moDCs. Data represents 
mean average expression levels ± SEM. For statistical analysis, paired students t-test was conducted 
between NT and gal9 siRNA-transfected cells. n.s. p >0.05, ** p < 0.005, *** p < 0.001.  
  
Figure S4. DC-SIGN is essential for particle uptake in DCs, Related to Figure 2. A and B moDCs 
were transfected with gal9 or a NT siRNA. Forty-eight hours later cells were incubated with AZN-D1 or 
isotype control (mIgG1) for 10 min prior to being challenged with zymosan for 60 min. Cells were then 
fixed, stained and the phagocytic index calculated. Graph and panels show representative results for 
one donor out of three independent experiments. Scale bar: 25 μm. C Quantification and statistical 
analysis of experiments shown in (A). Data represents mean average phagocytic index ± SEM of three 
independent donors. Results show the mean value ± SEM of three independent donors. Unpaired 
students t-test was conducted between NT and gal9 siRNA-transfected cells. n.s p > 0.05, * p < 0.05, ** 
p < 0.005, *** p < 0.001.   
 
Figure S5. Decreasing extracellular galectins by lactose does not alter the phagocytic ability of 
dendritic cells, Related to Figure 4. A. moDCs were treated with 35 mM lactose for 48 h and removal 
of extracellular Galectin-9 and Galectin-3 expression was confirmed by flow cytometry. Blue population 
= untreated cells; magenta population = lactose treated cells; black population = isotype control. 
Numbers in inset indicate gMFI. Panels depict representative results for one experiment out of three 
independent experiments. B. Control or lactose-treated cells were challenged with zymosan alone or in 
combination with 35 mM lactose for 60 min. Cells were then fixed, stained and the phagocytic index 
calculated. Graph shows representative results for one donor. Each dot represents phagocytic index 
obtained for each microscopical field, each of which contained 10-20 cells. C. Graph shows the mean 
value ± SEM for three independent donors. Unpaired students t-test was conducted between untreated 
control and lactose-treated cells. n.s p > 0.05.  
 
Figure S6. Treatment with cytochalasin D does not affect cell viability, Related to Figure 5. A and 
B. NT or gal9 siRNA-transfected moDCs were pre-treated with 1.25 μg/ml cytD for 5 (A) or 10 min (B) 
prior to being challenged with zymosan for 30 min. Cells were then fixed, stained and the phagocytic 
index calculated. Forty frames were analysed for each condition and donor. Data represents mean 
phagocytic index ± SEM for one representative donor out of two independent experiments. C. moDCs 
transfected as per (A) were treated with 5 μg/ml cytochalasin D (cytD) for 10 min. After this time cells 
were subjected to propidium iodide (PI) and Annexin V-FITC double staining for flow cytometry and 
percentage of apoptotic and necrotic cells calculated. One representative donor out-of-three 
independent experiments is shown. D. moDCs were transfected as in (A) and pre-treated with 2.5 μg/ml 
cytD for 10 min prior to being challenged with zymosan for 60 min. Cells were fixed, stained and the 
phagocytic index calculated. Twenty frames were analysed for each condition and donor. Data 
represents mean average phagocytic index ± SEM for one representative donor out-of-four independent 
experiments.  
 
 
 
 
 
Transparent Methods 
Generation of monocyte-derived dendritic cells 
 Dendritic cells were derived from peripheral blood monocytes isolated from a buffy coat 
(Sanquin, Nijmegen, The Netherlands) (de Vries et al., 2002). Monocytes isolated from healthy blood 
donors (informed consent obtained) were cultured for up to five days in RPMI 1640 medium (Life 
Technologies, Bleiswijk, Netherlands) containing 10 % foetal bovine serum (FBS, Greiner Bio-one, 
Alphen aan den Rijn, Netherlands), 1 mM ultra-glutamine (BioWhittaker), antibiotics (100 U/ml penicillin, 
100 µg/ml streptomycin and 0.25 µg/ml amphotericin B, Life Technologies), IL-4 (500 U/ml) and GM-
CSF (800 U/ml) in a humidified, 5 % CO2. On day 3, moDCs were supplemented with new IL-4 (300 
U/ml) and GM-CSF (450 U/ml). 
Generation of bone marrow-derived dendritic cells 
 Galectin-9-deficient mice were kindly provided by GalPharma (Takamatsu, Japan) and were 
described elsewhere (Seki et al., 2008). To generate bone marrow–derived DCs (BMDCs), bone marrow 
cells from mouse femurs were cultured in RPMI 1640 medium supplemented with 10 % FCS, 1 mM 
ultra-glutamine, antibiotics, and ß-mercaptoethanol in the presence of 20 ng/ml GM-CSF (PeproTech) 
for 8 days to generate GM-CSF BMDCs.  
Infection model and cytokine measurements 
Wild-type C57BL/6J (Charles River) and galectin-9 null mice were maintained under specific 
pathogen-free conditions at the Central Animal Laboratory (Nijmegen, the Netherlands). Drinking water 
and food were provided ad libitum. The experiments were performed according to guidelines for animal 
care of the Nijmegen Animal Experiments Committee and in accordance with the ethical standards 
described in the declaration of Helsinki. Endotoxin-free Candida albicans was prepared as described 
previously (van Spriel et al., 1999). Yeast cells were heat-inactivated by incubating them at 65 °C for 90 
minutes. Animals were injected with 12x106 heat-inactivated Candida albicans in a volume of 200 µl 
PBS intravenously and 3x106 in 50 µl PBS subcutaneously. Three hours after injection, spleen and 
popliteal lymph nodes were isolated and meshed to obtain single cell suspension. Spleen and lymph 
node cells were meshed through a 100 µm cell strainer by using a syringe plunger. Cell suspension was 
spun at 400xg for 5 min and resuspended in 3 ml of 1x ammonium chloride solution for the lysis of 
erythrocytes. After 3 min of incubation at room temperature cells were washed with 20 ml of PBS 
2 times. To analyse cytokine secretion, 380x103 lymph node cells or 1x106 spleen cells were seeded 
into 96-well plates for 24 h after which supernatants were collected and stored at -20 °C. Spleen samples 
were re-challenged with 1x106 C. albicans prior to being seeded for 24 h and supernatants collected. 
The levels of IL-12 and TNFα in the supernatants of spleen and lymph node homogenates were 
determined using a commercial ELISA kits (ThermoFisher Scientific). Standard curves were run at the 
same time and were used to calculate the concentration of cytokines in the samples. 
Antibodies and reagents 
 The following primary antibodies were used for Western Blotting: rabbit anti-DC-SIGN (H200, 
Santa Cruz, Heidelberg, Germany) at 1:2000 (v/v), goat anti-Galectin-9 (AF2045, R&D systems, 
Minneapolis, Minnesota) at 1:1000 (v/v) and rat anti-tubulin (Novus Biological, Abingdon, United 
Kingdom) at 1:2000 (v/v). The following secondary antibodies were used: donkey anti-rabbit IRDye 680 
926-32223, Li-Cor, Lincoln, Nebraska), donkey anti-goat IRDye 680 (920-32224, Li-Cor), goat anti-rat 
IRDye 680 (A21096, Invitrogen, Landsmeer, Netherlands). All secondary antibodies were used at 
1:5000 (v/v). 
 The following antibodies were used for fluorescence microscopy: mouse IgG2B anti-human DC-
SIGN at 2 μg/ml (DCN46, BD Biosciences, Breda, Netherlands), mouse IgG1 anti-human AZN-D1 at 2 
μg/ml (Geijtenbeek et al., 2000), goat anti-human Galectin-9 at 20 μg/ml (AF23045, R&D systems); 
mouse monoclonal Rac1 (240106; Cell Biolabs) at 1:100, TfR (sc-65877, Santa Cruz) at 1:200, anti-
FITC Alexa fluor 647 (Jackson ImmunoResearch, Huissen, Netherlands; 200-602-037) at 1:200. The 
following secondary antibodies were used: donkey anti-mouse IgG Alexa 647 (A31571), goat anti-
mouse IgG1 Alexa 488 (A21121), donkey-anti goat IgG Alexa 488 or 647 (A11055 and A21447), rabbit 
anti-mouse IgG Alexa 488 (A21204) and goat anti-mouse IgG2B Alexa 647 (A21242). All secondary 
antibodies were purchased from Life Technologies and used at 1:400 dilution (v/v). For F-actin staining 
Alexa fluor-647 phalloidin (A22287, Thermofisher) or Alexa fluor-568 phalloidin (A12380, Thermofisher) 
were used at 1:100 dilution (v/v). To inhibit specific cytoskeleton components cytochalasin D was used 
(C8273, Sigma-Aldrich, Zwijndrecht, Netherlands) at a final concentration of 1.25 or 2.5 μg/ml.  
Small interfering RNA knockdown 
 On day 3 of DC differentiation, cells were harvested and subjected to electroporation. For 
Galectin-9 and Galectin-3 silencing, three custom stealth small interfering RNA (siRNA) were used. For 
Galectin-9 LGALS9HSS142807, LGALS9HSS142808 and LGALS9HSS142809 were used and for 
Galectin-3 LGALS3HSS180668, LGALS3HSS180670, LGALS3HSS180669 (Invitrogen). Equal 
amounts of the siRNA ON-TARGETplus non-targeting (NT) siRNA#1 (Thermo Scientific) were used as 
control. Cells were washed twice in PBS and once in OptiMEM without phenol red (Invitrogen). For 
silencing each Galectin, a total of 15 μg siRNA (5 μg from each siRNA) was transferred to a 4-mm 
cuvette (Bio-Rad) and 5-10x106 DCs were added in 200 μl OptiMEM and incubated for 3 min before 
being pulsed with an exponential decay pulse at 300 V, 150 mF, in a Genepulser Xcell (Bio-Rad, 
Veenendaal, Netherlands), as previously described (Schuurhuis et al., 2009). Immediately after 
electroporation, cells were transferred to preheated (37 °C) phenol red–free RPMI 1640 culture medium 
supplemented with 1 % ultraglutamine, 10 % (v/v) FCS, IL-4 (300 U/ml), and GM-CSF (450 U/ml) and 
seeded at a final density of 5x105 cells/ml. 
Co-Immunoprecipitation and Western Blotting 
 Endogenous DC-SIGN was immunoprecipitated from lysates of moDCs (day 6) untreated or 
treated with 35 mM lactose for 48 h. Cells (10x106) were detached using cold PBS, collected and lysed 
in 1 ml lysis buffer containing 150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 1 % Brij97, 2 mM 
CaCl2, 5 mM NaF, 1 mM NaVO4 and 1 mM PMSF for 30 min on ice. Cell lysates were pre-cleared with 
3 % BSA and isotype control-coated Dynabeads (Invitrogen). Lysates were then incubated with 2 μg of 
anti-DC-SIGN (H200, SantaCruz) or isotype control under rotation. After incubating for 1 h at 4 °C, 
dynabeads were added and samples were further incubated for 1.5 h. Afterwards, beads were washed 
five times in washing buffer (150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 0.1 % Brij97, 2 mM 
CaCl2, 5 mM NaF, 1 mM NaVO4 and 1 mM PMSF) and bound proteins eluted in SDS sample buffer 
(62.5 mM Tris pH 6.8, 2 % SDS, 10 % glycerol). For immunoprecipitations performed on lactose-treated 
cells, 35 mM lactose was added to the lysis and wash buffer. Proteins were separated by PAGE and 
blotted onto PVDF membranes. Membranes were blocked in TBS containing 3 % BSA and 1 % skim 
milk powder at room temperature for 1 h prior to be stained with specific antibodies against DC-SIGN 
and Galectin-9. Antibody signals were detected with HRP coupled secondary antibodies and developed 
using Odyssey CLx (Li-Cor) following manufacturer’s instructions. Images were retrieved using the 
Image Studio Lite 5.0 software.  
Uptake assay and immunofluorescence 
 2x105 moDCs transfected with either non-targeting (NT) or gal9 siRNA were seeded in phenol 
red free RPMI containing 10 % FBS, 1 mM ultra-glutamine, antibiotics, IL-4 (500 U/ml) and GM-CSF 
(800 U/ml) in a humidified, 5 % CO2-containing atmosphere for 48 hours. After this time, cells were 
washed with serum free RPMI and challenged with 1x106 zymosan-FITC (ThermoFisher scientific) for 
15, 30 or 60 min, after which moDCs were washed extensively with PBA and fixed with 4 % 
paraformaldehyde (PFA). When appropriate, cells were incubated with 20 μg/ml of anti-DC-SIGN (AZN-
D1) or isotype control for 10 min prior to the addition of the zymosan-FITC particles. For experiments 
performed using cytoskeleton-blocking agents, cells were incubated with either 1.25 or 2.5 μg/ml of 
cytochalasin D for 10 min prior to the addition of zymosan-FITC particles. For lactose blocking 
experiments, moDCs were treated with growth medium containing 35 mM of lactose for 48 h. After this 
time, cells were detached and challenged in suspension with zymosan_FITC particles for 45 min prior 
to being seeded on Poly-L-Lyisine-coated coverslips. Cells were left to attach to the coverslip for further 
15 min in the presence of zymosan prior to being fixed with 4 % PFA and stained as above. 
 For immunofluorescence staining, samples were incubated without permeabilisation with an 
anti-FITC AF647 antibody (200-602-037, Jackson) at 1:200 (v/v) for 30 min at room temperature 
followed by DAPI staining (Sigma-Aldrich) at 1:3000 (v/v) for 10 min and at room temperature. Cells 
were then washed twice with PBS, one time with milliQ H2O, embedded onto glass slides using Mowiol 
(Calbiochem) and stored at – 20 °C until imaging. Samples were imaged with a Leica DMI6000 epi-
fluorescence microscope fitted with a 63x 1.4 NA oil immersion objective, a metal halide EL6000 lamp 
for excitation, a DFC365FX CCD camera and GFP and DsRed filter sets (all from Leica, Wetzlar, 
Germany). Focus was kept stable with the adaptive focus control from Leica. Images were analysed 
with ImageJ software. Twenty to thirty frames were analysed for each condition and the phagocytic 
index ((total number of particles –total number of membrane-bound particles)/number of cells) and the 
binding index (number or bound particles/number of cells) calculated for each frame.  
Flow cytometry 
 Single cell suspensions were stained with specific antibodies or isotype control as negative 
control for 30 min at 4 °C. The following antibodies were used: mouse-anti DC-SIGN (clone AZN-D1, 
(Geijtenbeek et al., 2000)) at 5 μg/ml; goat anti-Galectin-9 (AF2045, R&D systems) at 20 μg/ml. Before 
staining, moDCs and U-937 cells were incubated with 2 % human serum for 10 min on ice to block non-
specific interaction of the antibodies with FcRs. All secondary antibodies were conjugated to Alexa Fluor 
488 or Alexa Fluor 647 dyes (Invitrogen) and used at dilutions 1:400 (v/v). All antibody incubations were 
performed in PBA containing 2 % human serum. Unless otherwise stated, all flow cytometry stainings 
were performed against membrane-bound DC-SIGN and Galectin-9. For intracellular DC-SIGN and 
Galectin-9 stainings cells were fixed in 4 % PFA (w/v) for 10 min, permeabilised by incubation for 15 
min with PBA containing 0.1 % saponin (PBA-S) prior to being stained as before. For actin staining cells 
were fixed in 4 % PFA (w/v) for 10 min, permeabilised by incubation for 15 min with PBA containing 0.1 
% saponin (PBA-S) and F-actin subsequently labelled with Alexa Fluor 647-labelled phalloidin in PBA-
S for 20 min at room temperature. Cells were analysed with a FACSCalibur instrument (BD Biosciences) 
and results analysed using FlowJo version X software (Tree Star, Ashland, Oregon).  
Confocal microscopy 
 gal9 or non-targeting siRNA –transfected moDCs were collected at day 5 and blocked with PBA 
+ 1 % human serum prior to being incubated with primary antibody for 30 min on ice. Cells were then 
washed and incubated for further 30 min with the corresponding secondary antibody followed by a 60 
min incubation at 12 ° C. Cells were then washed extensively, fixed in 2 % PFA and allowed to attach 
on poly-L-lysine-coated 12 mm glass coverslips (Electron Microscopy Sciences, Hatfield, Pennsylvania) 
for 30 min at room temperature. After, cells were again fixed with 2 % PFA for 20 min, washed with PBS 
and coverslips embedded in glass slides using Mowiol prior to be stored at 4 °C until imaging. For actin 
staining, cells were fixed with 4 % PFA for 20 min at 4 °C, washed twice and permeabilised by incubation 
with PBA containing 0.1 % saponin (PBA-S). F-actin was subsequently labelled with Alexa Fluor 647-
labelled phalloidin in PBA-S for 30 min at room temperature. Confocal images were obtained in a 
sequential manner using a commercial Olympus FV1000 Confocal Laser Scanning Microscope with 
Argon (457, 488, 515 nm), and 405, 559 and 635 diode excitation lasers and a 60× oil immersion 
objective (UPlanSApo 60×/1.35 Oil). Images were obtained using the FW10-ASW software (Olympus, 
Nijmegen, Netherlands) and processed with Fiji software.  
Ventral plasma membrane staining and super resolution imaging 
 5x105 moDCs were seeded onto 25 mm glass coverslips (Electron Microscopy Sciences, 
Hatfield, Pennsylvania) in phenol red free RPMI containing 10 % FBS, 1 mM ultra-glutamine, IL-4 (500 
U/ml) and GM-CSF (800 U/ml) in a humidified, 5 % CO2-containing atmosphere for 48 hours. After this 
time, ventral plasma membranes were prepared by sonication using a Sartorius Labsonic P sonicator 
with cycle set at 1 and amplitude at 20 % output. First, the sonicator tip was placed in a glass beaker 
containing 100 ml prewarmed hypotonic PHEM buffer (6 mM PIPES, 5 mM HEPES, 0.4 mM Mg2SO4, 2 
mM EGTA). Next, coverslips were held 1-2 cm below the sonicator tip at a 45 degrees angle in the 
hypotonic PHEM solution and cells were sonicated for approximately 1 second. Directly after sonication 
coverslips were transferred to a pre-warmed PBS solution containing 4 % paraformaldehyde and 0.05 
% glutaraldehyde and incubated for 30 min at room temperature. For Galectin-9 and actin staining, 
coverslips were subsequently incubated with anti-Galectin-9 antibody (AF23045, R&D systems) for 2 h 
at room temperature, washed and incubated for 1 h with the secondary antibody donkey-anti-goat Alexa 
568 (A11057) at 1:200 (v/v) and Alexa Fluor 488-labelled phalloidin at 1:100 (v/v) followed by DAPI 
staining (Sigma-Aldrich) at 1:3000 (v/v) for 10 min and at room temperature. Cells were then washed 
twice with PBS, one time with milliQ H2O, embedded onto glass slides using Mowiol (Calbiochem) and 
stored at 4 °C until imaging. Confocal images were obtained in a sequential manner using a commercial 
Zeiss LSM880 confocal scanning microscope equipped with an Airyscan Unit, 405 and 561 nm diode 
lasers, argon (458, 488, 514 nm) lasers and a 633 nm laser and a 63× Plan Apochromat (1.4 NA) oil 
immersion objective. Images were obtained using the ZEN software (Zeiss Microscopy, Breda, 
Netherlands) and processed with the ZEN Airyscan processing toolbox and Fiji software.  
Atomic force microscopy 
 6x105 moDCs transfected with either Non-Targeting or gal9 siRNA were seeded in phenol-red 
free RPMI supplemented as before in a 40 mm glass bottom dish (GWST-5040, WillCo, Amsterdam, 
Netherlands) for 48 hours. After this time, mechanical probing of cells was performed with a Catalyst 
BioScope (Bruker, Kalkar, Germany) atomic force microscope coupled to a confocal microscope (TCS 
SP5II, Leica) using the “point and shoot” feature of the Nanoscope software (Bruker). Silicon nitride 
cantilevers with nominal spring constants of 0.06 N/m (S-NL type D, Bruker) were used without any tip 
modification. The system was calibrated first in air and then in cell-free medium at 37 °C prior to each 
experiment by measuring the deflection sensitivity on a glass surface, which enabled determination of 
the cantilever spring constant using the thermal noise method (te Riet et al., 2011). Before the sample 
was placed, the xy movement of the sample stage was calibrated using the NanoScope software. An 
optical image of the cells was captured after the tip position was registered, which allowed for selection 
of the point (or region) of interest on the optical image. Two force − distance curves were sequentially 
acquired from each point selected on the membranes of stretched cells and three independent points 
were probed for each cell. The forward (approach) and reverse (retraction) velocities were kept constant 
at 1 μm/s, ramping the cantilever by 4 μm with a 3 nN threshold in a closed z loop. After baseline 
correction, approach curves were analysed for determination of Young’s modulus of elasticity using 
Sneddon’s conical indenter model (Sneddon, 1965) for which Poisson’s ratio was set as 0.5 (Lin et al., 
2007) and the half angle of the indenter as 18°. Contact point-independent linearised Sneddon equation 
was used for fitting the approach curves (van Helvert and Friedl, 2016).  The region on the approach 
curve through which the model was fit was determined via setting the lower and upper boundaries that 
corresponded to approximately 10 % and 70 % of the difference between the maximum and minimum 
forces exerted, respectively. Two curves per point and 2-3 points per cell were averaged to obtain 
Young’s modulus of elasticity per cell. Approximately 10 to 30 cells were analysed for each condition 
and experiment.  
Rac1-GTPase activation assay 
 To assess GTP-bound Rac1 levels, colorimetric G-LISA activity assay kit (BK128-S, 
Cytoskeleton, Denver, Colorado) was used according to manufacturer’s instructions. Day 5 moDCs were 
stimulated with zymosan particles (Z4250, Sigma-Aldrich) for 5, 15 or 30 min prior to being lysed in ice-
cold lysis buffer, snap-frozen in liquid nitrogen and stored at -80 °C. Protein concentrations were 
determined using the micro BCA protein assay kit (23235, ThermoFisher scientific) and 50 μg of total 
protein were subsequently used for the G-LISA assay. Rac1-GTP levels were determined using the 
Rac1-GTP binding 96-well plates. Absorption of the wells at 490 nm was determined with an iMark 
microplate reader (BioRad).   
Statistical analysis 
 All data was processed using Excel 2013 (Microsoft) and GraphPad Prism 5 software. All Image 
processing was performed on ImageJ software and statistical analysis was done using Prism5. The 
specific statistical test used is described for each figure in the figure legend. p values < 0.05 were 
considered statistically significant. 
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